Latest Schedule 13G passive stakes

Sculptor Capital LP and its affiliates have reported a 4.43% beneficial ownership stake, totaling 523,144 Class A ordinary shares, in Cantor Equity Partners VI, Inc. as of March 31, 2026.

Extract Advisors LLC and associated entities have disclosed a combined 6.6% beneficial ownership stake in Anfield Energy Inc. as of March 2026.

Vestal Point Capital, LP and Ryan Wilder have reported a 6.5% passive ownership stake in Alto Neuroscience, Inc., totaling over 2 million shares.

Manulife Financial Corporation and its subsidiaries have reported a combined beneficial ownership stake of approximately 5.03% in Citizens Community Bancorp, Inc.

Vestal Point Capital, LP has reduced its ownership in Immatics N.V. to 4.6%, crossing below the 5% regulatory reporting threshold.

Caracola Ventures Corp has disclosed a beneficial ownership of 5,050,000 shares in New ERA Energy & Digital, Inc., representing an 8.6% stake in the company.

Vestal Point Capital and Ryan Wilder have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Arcellx, Inc.

Cinctive Capital Management has filed an amended Schedule 13G reporting an 11.8% beneficial ownership stake in Lifezone Metals Ltd.

Vestal Point Capital, LP and Ryan Wilder have filed an amendment reporting a 0% beneficial ownership stake in Day One Biopharmaceuticals, Inc.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5% beneficial ownership stake in Bright Minds Biosciences Inc.

American Capital Management, Inc. has filed an amended Schedule 13G reporting a 5.6% beneficial ownership stake in Cerence, Inc.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Nurix Therapeutics, Inc.

Citadel Securities and affiliated entities have filed a Schedule 13G reporting a 3.7% beneficial ownership stake in TeraWulf Inc. common stock.

Vestal Point Capital and Ryan Wilder have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aprea Therapeutics, Inc.

Darsana Capital Partners LP has reported an 8.1% beneficial ownership stake in Warner Music Group Corp. Class A common stock.

PointState Capital LP and Zachary J. Schreiber have filed an amended Schedule 13G reporting a 6.4% beneficial ownership stake in StubHub Holdings, Inc.

Darwin Global Management and Dr. Abhishek Trehan have reported a 7.8% beneficial ownership stake in Insmed Incorporated.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5.5% beneficial ownership stake in Immunocore Holdings plc.

David T. Lu and associated entities Hedgehog Capital LLC and Hold River LLC have reported a 6.1% beneficial ownership stake in Bluerock Homes Trust, Inc.

Sculptor Capital Management has filed a Schedule 13G reporting beneficial ownership of 674,100 Class A ordinary shares in Paloma Acquisition Corp I.

Ikarian Capital, LLC and Neil Shahrestani have filed an exit notice, reporting 0% beneficial ownership in Karyopharm Therapeutics Inc.

Cinctive Capital Management LP and its affiliates have reported a 9.99% beneficial ownership stake in NeOnc Technologies Holdings, Inc. as of March 31, 2026.

Tenor Capital Management, Tenor Opportunity Master Fund, and Robin Shah have filed a Schedule 13G reporting a 4.3% beneficial ownership stake in Cambridge Acquisition Corp.

Warburg Pincus entities have filed an exit notice confirming they no longer hold any shares of Sotera Health Co.

Warren Buffett and Berkshire Hathaway entities report a 9.4% beneficial ownership stake in The New York Times Company.

Warren Buffett and Berkshire Hathaway entities report a 9.4% beneficial ownership stake in The New York Times Company.

Warren Buffett and Berkshire Hathaway entities report a 0.4% beneficial ownership stake in Constellation Brands, Inc.

Warren Buffett and Berkshire Hathaway entities report a 0.4% beneficial ownership stake in Constellation Brands, Inc.

Ikarian Capital, LLC and Neil Shahrestani have reported a 7.7% beneficial ownership stake in Pelthos Therapeutics Inc. via a Schedule 13G filing.

Citadel Securities and affiliated entities have filed a Schedule 13G reporting a 0.3% beneficial ownership stake in Urban One, Inc.